ASCO: Bristol-Myers Squibb and Merck Don't Disappoint

We knew going into American Society of Clinical Oncology annual meeting that immuno-oncology would be a big focus. And Bristol-Myers Squibb and Merck didn't disappoint.

Rather than attacking the tumor directly, immuno-oncology drugs encourage the patient's immune system to attack the cancer. Bristol-Myers Squibb already has Yervoy on the market, a drug that activates the immune system. And both Bristol-Myers Squibb and Merck are developing a second class of immuno-oncology drug, called PD1 inhibitors, that inhibit a signal that tumor cells use to tell the immune system to not attack them. Inhibiting the inhibitor results in activation of the immune system.

The PD1 drugs have already put up remarkable data in patients with melanoma, but at ASCO, Bristol-Myers Squibb and Merck showed the class's true potential, expanding their use into other types of cancer. Merck's MK-3475 worked well in head and neck cancer, producing a 45% response rate in patients that over-express the target protein. And Bristol-Myers Squibb showed that nivolumab worked well in kidney cancer in combination with Yervoy, with the response rate about double what the monotherapy produced.

Watch the following video for more insight into the oncology confab from senior biotech specialist Brian Orelli and health-care analyst David Williamson.

Will this stock be your next multibagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

The article ASCO: Bristol-Myers Squibb and Merck Don't Disappoint originally appeared on

Brian Orelli and The Motley Fool have no position in any stocks mentioned. David Williamson owns shares of Merck. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story